← Eichor
Study identifier: NCT07442591 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Assess Effect of Dosing Intervals on Multiple-Dose Pharmacokinetics of WD-1603 Taken Before Meals in Healthy Participants

Condition: Healhty  ·  Sponsor: Shanghai WD Pharmaceutical Co., Ltd.

PhasePhase 1
Planned participants12
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603. The main question we want to answer is: * How does the body process WD-1603 when it is taken by different time intervals? What will participants do? * Participants will take one tablet of WD-1603 twice a day on three separate days. * On each dosing day, the two doses will be spaced different hours apart. * Between each dosing day, there will be a rest period of up to 7 days.

This description comes directly from the study's public registry record.

Talk to the study team

Danyong Zhang, Master  ·  +86-138-1672-0823  ·  danyong.zhang@wdpharma.com

Yan Jiao, Master  ·  +86-180-1937-4596  ·  yan.jiao@wdpharma.com

Always discuss trial participation with your own doctor first.

Locations (1)

Shanghai Xuhui Central HospitalShanghai, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07442591